Stratus Medical, a leading medical device company, has recently announced the initiation of enrolment for its Nimbus RF device clinical trial. The trial is designed to evaluate the safety and efficacy of the device in treating patients with chronic pain.

The Nimbus RF device is a novel, non-invasive medical device designed to provide relief from chronic pain. It works by delivering radiofrequency energy to the affected area, which helps to reduce inflammation and pain. The device is intended to be used in conjunction with other treatments such as physical therapy and medications.

The clinical trial will involve a total of 40 patients, who will be randomly assigned to either receive the Nimbus RF device or a sham treatment. The primary outcome measure of the trial will be the patient’s pain levels, which will be assessed using the Visual Analogue Scale (VAS). Secondary outcomes will include changes in quality of life, functional ability, and patient satisfaction.

The trial is expected to last for 12 weeks, with follow-up visits scheduled at 6 and 12 weeks after treatment. The primary endpoint of the trial will be assessed at 12 weeks. The results of the trial will be used to determine if the Nimbus RF device is safe and effective for treating chronic pain.

Stratus Medical is committed to providing innovative solutions for patients suffering from chronic pain. The initiation of the Nimbus RF device clinical trial is an important step towards achieving this goal. If successful, the device could provide relief to millions of people suffering from chronic pain.

The results of the trial are expected to be available in 2021. In the meantime, Stratus Medical is continuing to develop other innovative treatments for chronic pain.

Source: Plato Data Intelligence: PlatoAiStream